Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery

Pilot Study for Zoledronic Acid to Prevent High-Turnover Bone Loss After Bariatric Surgery

This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.

The investigators are evaluating the ability of a single dose of zoledronic acid to improve bone outcomes after RYGB or SG surgery. The investigators have previously shown that RYGB and SG have negative effects on bone density, bone microarchitecture, and that bariatric procedures potentially increase the risk of fractures. The purpose of this study is to evaluate the safety and efficacy of zoledronic acid to prevent the high-turnover bone loss that occurs in adults who have chosen to undergo RYGB or SG.

Inclusion Criteria:

• Men must be age ≥ 50
• Women must be age ≥ 25 and postmenopausal
• Planning to receive RYGB or SG surgery

Exclusion Criteria:

• Age < 25
• Prior bariatric surgery
• Weight ≥ 400 lbs
• Liver or renal disease
• Hypercalcemia, hypocalcemia, or hypomagnesemia
• Serum 25-hydroxyvitamin D < 20 ng/mL
• History of bone-modifying disorders
• Use of bone-active medications
• Known sensitivity to bisphosphonates
• Extensive dental work involving extraction or dental implant within the past 2 months or planned in the upcoming 6 months